Announcing IndieBio SF’s Next Wave – VC-Founder Meetings (June 17 to 21) Learn More

Karma Biotechnologies

LNP technology that can deliver both DNA and RNA payloads to solid tumor microenvironments


Andrew Gray

Past-CEO & Co-Founder / CEO & Co-Founder

Joseph Turner

President, CFO, and CBO

Alan Johnson

COO & Co-founder

Company details

Karma is an in vivo cell therapy company that uses a proprietary LNP technology to reprogram key immune cells to infiltrate tumors and break down their defenses from within. Karma’s ionizable LNPs can target and reprogram macrophages within the spleen using DNA., RNA, or both, which can then home to tumor sites and produce therapeutics directly within the tumor microenvironment. Karma’s technology is initially focused on cytokines and other biologicals, such as IL-15, locally within tumors and metastatic sites. Localized IL-15 production can turn cold tumors hot, potentiating immunotherapies while avoiding the dangers of systemic toxicity. Karma will advance through their own internal drug program while also partnering in parallel. The company already has an active paid partnership with a public pharma company and is in post-LOI discussions around another paid partnership early next year.

Get In Touch with Karma Biotechnologies

Please tell us a little bit about yourself and why you'd like to get connected. Karma Biotechnologies + SOSV will follow up with you via email.


No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.